Results 151 to 160 of about 9,620 (164)

Canakinumab for the treatment of adult-onset Still’s disease

Expert Review of Clinical Immunology, 2020
Paolo Sfriso, Andrea Doria, Paola Galozzi   +2 more
exaly  

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

Lancet, The, 2018
Marcus Flather, Prem Pais, Tom Thurén   +2 more
exaly  

Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes

Expert Review of Clinical Immunology, 2010
Michael F Mcdermott
exaly  

Canakinumab in Schnitzler Syndrome

Seminars in Arthritis and Rheumatism, 2013
Steven Vanderschueren
exaly  

Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody

Clinical Pharmacokinetics, 2012
Stacey Tannenbaum, Philip Lowe, Hermann Gram   +2 more
exaly  

Canakinumab for the treatment of hyperimmunoglobulin D syndrome

Expert Review of Clinical Immunology, 2019
Judith Sánchez-Manubens, Jordi Anton, Estibaliz Iglesias   +2 more
exaly  

Canakinumab

Reactions Weekly, 2015
openaire   +2 more sources

Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians

Therapeutic Advances in Musculoskeletal Disease, 2013
Jasmin Kuemmerle-Deschner
exaly  

Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis

Journal of Clinical Pharmacology, 2013
exaly  

Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis

Journal of Clinical Pharmacology, 2016
exaly